1. Home
  2. PBH vs ZYME Comparison

PBH vs ZYME Comparison

Compare PBH & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc.

N/A

Current Price

$45.10

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$25.99

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PBH
ZYME
Founded
1996
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
PBH
ZYME
Price
$45.10
$25.99
Analyst Decision
Buy
Strong Buy
Analyst Count
7
13
Target Price
★ $67.80
$41.23
AVG Volume (30 Days)
451.4K
★ 494.2K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ 0.61
N/A
Revenue
★ $975,777,000.00
$105,965,000.00
Revenue This Year
$17.03
$186.92
Revenue Next Year
$6.06
$16.24
P/E Ratio
$76.54
★ N/A
Revenue Growth
36.77
★ 38.87
52 Week Low
$42.62
$16.00
52 Week High
$71.07
$31.34

Technical Indicators

Market Signals
Indicator
PBH
ZYME
Relative Strength Index (RSI) 39.28 47.17
Support Level $44.73 $22.10
Resistance Level $49.79 $27.30
Average True Range (ATR) 1.30 1.09
MACD -0.01 -0.14
Stochastic Oscillator 32.07 33.08

Price Performance

Historical Comparison
PBH
ZYME

About PBH Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: